Page 1223 - Cote clinical veterinary advisor dogs and cats 4th

Lymphoma, Multicentric (Dog) 611

BSA Correlations for Dogs • Phenotype (B-cell better than T-cell
lymphoma)
2
Weight, kg (lb)
2
BSA, m
Weight, kg (lb)
BSA, m
VetBooks.ir 0.5 (1) 0.06 41 (90) 1.19 • Mediastinal mass (negative prognostic Diseases and Disorders
• Hypercalcemia (negative prognostic indicator,
likely due to association with T-cell phenotype)
1.21
42 (92.5)
0.1
1 (2)
phenotype)
2 (4.5) 0.15 43 (94.5) 1.23 indicator, likely due to association with T-cell
3 (6.5) 0.2 44 (97) 1.25 • Serum markers: thymidine kinase (sTK),
lactate dehydrogenase (LDH), ferritin
4 (9) 0.25 45 (99) 1.26
• Administration of prior prednisone (negative
5 (11) 0.29 46 (101) 1.28 prognostic indicator, possibly due to induc-
6 (13) 0.33 47 (103.5) 1.3 tion of multidrug resistance or masking of
higher-stage disease)
7 (15.5) 0.36 48 (105.5) 1.32
• Other factors impacting prognosis: Ki67,
8 (17.5) 0.40 49 (108) 1.34 AgNOR (argyrophilic nucleolar organizer
9 (20) 0.43 50 (110) 1.36 region) staining, modified Glasgow prognos-
10 (22) 0.46 51 (112) 1.39 tic score (mGPS), CCND1 gene expression,
chromosomal aberrations, older age, anorexia,
11 (24.5) 0.49 52 (114.5) 1.41 anemia, fever, dyspnea, thrombocytopenia,
12 (26.5) 0.52 53 (116.5) 1.43 hypoalbuminemia, and chronic inflammatory
13 (28.5) 0.55 54 (119) 1.44 disease
14 (31) 0.58 55 (121) 1.46 PEARLS & CONSIDERATIONS
15 (33) 0.6 56 (123) 1.48
16 (35) 0.63 57 (125.5) 1.5 Comments
• Lymphoma is a common canine malignancy.
17 (37.5) 0.66 58 (127.5) 1.51
• The majority of dogs with lymphoma can
18 (39.5) 0.69 59 (130) 1.53 achieve a CR when treated with chemo-
19 (42) 0.71 60 (132) 1.55 therapy, and treatment can be very rewarding
20 (44) 0.74 61 (134) 1.57 for the pet owner and veterinarian.
• Identification of prognostic factors may help
21 (46) 0.76 62 (136.5) 1.58 predict an individual’s response to treatment
22 (48.5) 0.78 63 (138.5) 1.6 and guide the decision on whether to pursue
23 (50.5) 0.81 64 (141) 1.62 treatment.
• An understanding of the relative efficacy and
24 (53) 0.83 65 (143) 1.64
potential toxicoses of the various protocols
25 (55) 0.85 66 (145) 1.65 aids in determining the best treatment
26 (57) 0.88 67 (147.5) 1.67 protocol for an individual animal.
• Differentiation of cell type (phenotype)
27 (59.5) 0.9 68 (149.5) 1.68
is prognostic and may guide treatment
28 (61.5) 0.92 69 (152) 1.7 decisions. B-cell lymphoma carries a more
29 (64) 0.94 70 (154) 1.72 favorable prognosis than T-cell lymphoma
30 (66) 0.96 71 (156) 1.74 (“B is better”), and B-cell lymphoma makes
up the majority of cases of lymphoma in
31 (68) 0.99 72 (158.5) 1.75 dogs.
32 (70.5) 1.01 73 (160.5) 1.77
Technician Tips
33 (72.5) 1.03 74 (163) 1.78
Technicians handling chemotherapeutic drugs
34 (75) 1.05 75 (165) 1.8
must have received appropriate training regard-
35 (77) 1.07 76 (167) 1.81 ing drug handling, avoidance of unintended
36 (79) 1.09 77 (169.5) 1.83 exposure, proper disposal, management of spills,
and other complications.
37 (81.5) 1.11 78 (171.5) 1.84
38 (83.5) 1.13 79 (174) 1.86 SUGGESTED READING
39 (86) 1.15 80 (176.5) 1.88 Vail DM: Canine lymphoma and lymphoid leuke-
40 (88) 1.17 mias. In Withrow SJ, et al, editors: Withrow &
MacEwen’s Small animal clinical oncology, St. Louis,
BSA, Body weight–to–body surface area correlation. 2013, Saunders, pp 608-638.
AUTHOR: Laurel E. Williams, DVM, DACVIM
EDITOR: Kenneth M. Rassnick, DVM, DACVIM
• Sex (females better than males) although low-grade lymphoma is often
• Weight (small dogs better than large dogs, associated with comparable survival times
although possibly influenced by dosing with less intensive chemotherapy due to its
regimen) chronic indolent nature)
• Histologic grade (high-grade lymphoma has • Stage and substage (I, II, or III better than
a higher CR rate than low-grade lymphoma, IV or V; a better than b)

www.ExpertConsult.com